HOOKIPA Pharma Inc
NASDAQ:HOOK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.74
2.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
HOOKIPA Pharma Inc
Income from Continuing Operations
HOOKIPA Pharma Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
HOOKIPA Pharma Inc
NASDAQ:HOOK
|
Income from Continuing Operations
-$73.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$2.4B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$8.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
46%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.6B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
8%
|
CAGR 10-Years
23%
|
|
HOOKIPA Pharma Inc
Glance View
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.
See Also
What is HOOKIPA Pharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-73.3m
USD
Based on the financial report for Mar 31, 2025, HOOKIPA Pharma Inc's Income from Continuing Operations amounts to -73.3m USD.
What is HOOKIPA Pharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-10%
Over the last year, the Income from Continuing Operations growth was -54%. The average annual Income from Continuing Operations growth rates for HOOKIPA Pharma Inc have been 1% over the past three years , -10% over the past five years .